Gram-positive bacteria cause serious human illnesses through combinations of cell surface and secreted virulence factors. We initiated studies with four of these organisms to develop novel topical antibacterial agents that interfere with growth and exotoxin production, focusing on menaquinone analogs. Menadione, 1,4-naphthoquinone, and coenzymes Q1 to Q3 but not menaquinone, phylloquinone, or coenzyme Q10 inhibited the growth and to a greater extent exotoxin production of Staphylococcus aureus, Bacillus anthracis, Streptococcus pyogenes, and Streptococcus agalactiae at concentrations of 10 to 200 g/ml. Coenzyme Q1 reduced the ability of S. aureus to cause toxic shock syndrome in a rabbit model, inhibited the growth of four Gram-negative bacteria, and synergized with another antimicrobial agent, glycerol monolaurate, to inhibit S. aureus growth. The staphylococcal two-component system SrrA/B was shown to be an antibacterial target of coenzyme Q1. We hypothesize that menaquinone analogs both induce toxic reactive oxygen species and affect bacterial plasma membranes and biosynthetic machinery to interfere with two-component systems, respiration, and macromolecular synthesis. These compounds represent a novel class of potential topical therapeutic agents.
G
ram-positive bacteria cause large numbers of infections; some of these organisms and their toxic products, including Bacillus anthracis and Staphylococcus aureus enterotoxins (SEs), are select agents of bioterrorism. S. aureus, Streptococcus pyogenes, and Streptococcus agalactiae cause infections which range from relatively benign to life-threatening, such as toxic shock syndrome (TSS) (1) (2) (3) (4) (5) (6) (7) . For example, S. aureus secretes the superantigen TSS toxin 1 (TSST-1), which is the predominant cause of menstrual TSS and up to 50% of nonmenstrual TSS (8, 9) . Staphylococcal enterotoxin superantigens, notably serotypes B and C, cause the remaining 50% of nonmenstrual TSS cases. Staphylococcal superantigens cause TSS through overproduction of cytokines (4, (9) (10) (11) .
We and others have identified Gram-positive two-component systems (TCS) that affect virulence and ability to interact with the external environment (12) (13) (14) . We hypothesized that one or more of these critical TCS may be regulated by menaquinone. Part of the basis for this hypothesis is that many compounds we have tested, including positively charged hemoglobin peptides (15) , clindamycin (16) , glycerol monolaurate (GML) (17, 18) , and chitosan (19) , although disparate in properties, appear in part to target S. aureus and Streptococcus pyogenes bacterial TCS signaling, with the consequence being reduction of growth and/or exotoxin production. This suggests that it may be possible to find menaquinone analogs that also inhibit Gram-positive bacterial growth and exotoxin production, forming the basis for our studies. Although we primarily tested effects of menaquinone analogs on Gram-positive bacteria, studies were performed also with four Gram-negative bacteria.
MATERIALS AND METHODS
Bacteria. S. aureus MN8 and CDC587 are typical methicillin-sensitive menstrual TSS isolates (9) . S. aureus MNPE is a methicillin-sensitive nonmenstrual TSS isolate from a case of fatal postinfluenza pneumonia (20) ; this organism has a wild-type alpha-toxin gene. All three of these organisms belong to clonal group USA200. Community-associated methicillinresistant S. aureus (CA-MRSA) MW2 (clonal group USA400) was isolated from a fatal case of necrotizing pneumonia in the upper Midwest (21) .
CA-MRSA LAC (clonal group USA300) was isolated from a skin infection (22) . Ten recent clinical isolates included 2 methicillin-sensitive S. aureus (MSSA) isolates (USA200) and 8 CA-MRSA isolates (2 USA200, 3 USA300, and 3 USA400). Bacillus anthracis Sterne was purchased from the Colorado Serum Company, Denver, CO. Streptococcus pyogenes strain MNWA is an M3 isolate from a TSS patient. Streptococcus agalactiae strain MNSI is an isolate from a patient with neonatal sepsis. Escherichia coli, Salmonella enterica serotype Typhimurium, Bordetella bronchiseptica, and Gardnerella vaginalis were clinical isolates maintained in the laboratory.
A complete deletion of MN8 srrAB, the genes for the SrrA/B TCS, was achieved by first amplifying upstream of srrA via PCR with the primer set EcoRIsrrAupF (5=-AAAGAATTCCCTGTTGGTCGTTTAGACTATGAT A-3=) and srrAupRev (5=-CATGCGTTCTGAAATAACTATATTCAATT CACACATGCTTTTCTTTACAAAAGT-3=) and downstream of srrB with the primer set srrBdnF (5=-AATTGAATATAGTTATTTCAGAACG CATG-3=) and KpnIsrrBdnRev (5=-AAGGTACCCGCCACTACCTACA ACATTG-3=). The fragments were then spliced together by use of overlapping PCR with the primer set EcoRIsrrAupF and KpnIsrrBdnRev, digested with EcoRI and KpnI, and inserted into pJB38, a derivative of pKOR1 (23) . The resulting plasmid, henceforth referred to as pJB38-⌬srrAB, was transformed into E. coli DH5␣, with selection of plasmid by growth in 100 g/ml of ampicillin in Luria-Bertani broth. Plasmid was isolated with use of a mini-plasmid isolation kit (IBI Scientific, Peosta, IA) and transformed into S. aureus strain RN4220, with selection with 10 g/ml of chloramphenicol. The plasmid was then transformed into S. aureus MN8, and selection was performed according to the original pKOR1 protocol (23) . Deletions of srrAB were detected using external primers to the deletion construct and confirmed by the decrease in band size equal to the srrAB gene pair. Loss of the plasmid was confirmed by streaking colonies with confirmed deletion on Todd-Hewitt (TH) broth plates containing 10 g/ml of chloramphenicol.
Menaquinone and analogs. Menaquinone and analogs (menadione, 1,4-naphthoquinone, phylloquinone, coenzymes Q1 to Q3, and coenzyme Q10) were purchased from Sigma-Aldrich, St. Louis, MO. The compounds were studied in vitro in dose-response experiments with concentrations ranging from 0 to 200 g/ml.
Menaquinone analog effects on S. aureus and exotoxin production. For aerobic studies of S. aureus, strains MN8 (and an srrAB knockout mutant), CDC587, MNPE, MW2, and LAC and 10 recent clinical isolates (starting inocula of 10 6 to 10 7 /ml) were cultured in triplicate in 25 ml of TH broth for 1 to 24 h with shaking (200 revolutions/min) in the presence and absence of potential antimicrobial compounds. After incubation, a sample of culture was used to determine CFU/ml, and samples of MN8, an srrAB knockout mutant of MN8, CDC587, and MNPE with capability to produce TSST-1 were used for TSST-1 quantification by Western immunoblot analysis (15) . Alpha-toxin was quantified by bioassay through lysis of rabbit erythrocytes (24) . Purified TSST-1 and alpha-toxin were used in standard curve generation (24, 25) .
For anaerobic chamber experiments, S. aureus MN8 was cultured stationary for 24 h in prereduced TH broth containing various concentrations of antimicrobial agents and then assayed for CFU/ml. The chamber was monitored for maintenance of anaerobic conditions.
Menaquinone analog effects on other bacteria. Organisms were cultured in triplicate in 25 ml of TH broth at 37°C for up to 24 h with antimicrobial compounds. B. anthracis Sterne and G. vaginalis were cultured aerobically at 37°C with shaking at 100 revolutions/min; the Gardnerella culture was supplemented with 10% human serum. Streptococci were incubated for up to 24 h, with organisms grown stationary in the presence of 7% CO 2 . E. coli, Salmonella Typhimurium, and Bordetella bronchiseptica were cultured aerobically at 37°C for up to 24 h with shaking at 200 revolutions/min.
GML synergy with coenzyme Q1. Glycerol monolaurate (GML) was purchased from Colonial Chemical Company, South Pittsburg, TN. A stock solution of GML was prepared in absolute ethanol (100 mg/ml) and diluted into TH broth. TH broths were inoculated with GML (10 g/ml) or the corresponding volume of absolute ethanol plus various concentrations of coenzyme Q1. The media were then inoculated with S. aureus MN8. An additional set of flasks contained GML alone at 10 g/ml and 100 g/ml. All flasks were incubated aerobically for 24 h with shaking at 200 revolutions/min, and CFU/ml were determined.
Rabbit model for TSS. Experiments were performed under an approved IACUC protocol. A subcutaneous-abscess model was used to assess the ability of coenzyme Q1 to prevent TSS. Wiffle golf balls were implanted subcutaneously in the flanks of Dutch belted rabbits of either sex (26) . Then, 1.5 ml of the 30 ml of serous fluid within the golf balls was removed and replaced with coenzyme Q1 (0.5 mg in 0.5 ml of ethanol) or a vehicle (0.5 ml of ethanol) plus S. aureus MN8 (1.5 ϫ 10 10 in a 1.0-ml volume). Rabbits were monitored for up to 1 week for development of lethal TSS. Rabbits were prematurely euthanized when they simultaneously could not right themselves and failed to exhibit escape behavior; this point is 100% predictive of lethal TSS.
Statistics. Effects of menaquinone and analogs on growth are presented as means Ϯ standard deviations (SDs). Differences in means were calculated using Student's t test analysis of unpaired data. Differences in rabbit survival were calculated with Fisher's exact test.
RESULTS
Menaquinone, phylloquinone, and coenzyme Q10 do not inhibit bacterial growth. The structures of menaquinone, menadione, 1,4-naphthoquinone, and coenzyme Q are shown in Fig. 1 . The phylloquinone structure is that of menaquinone with C 15 H 31 added to the menaquinone bracketed side chain. The difference among the coenzyme Q molecules is the number of isoprenyl units in the side chain designated with the brackets, where n ϭ 1 to 10 for coenzymes Q1 to Q10. Menaquinone, phylloquinone, and coenzyme Q10 lacked antimicrobial activity at any concentration (0 to 200 g/ml) in 24-h cultures (Table 1) . These three compounds also did not inhibit production of TSST-1 by S. aureus MN8, CDC587, and MNPE. In time course experiments (1 to 24 h), neither menaquinone nor phylloquinone inhibited S. aureus MN8 growth.
Menadione, 1,4-naphthoquinone, and coenzymes Q1 to Q3 inhibit bacterial growth. The menaquinone analogs menadione, 1,4-naphthoquinone, and coenzymes Q1 to Q3 exhibited activity against the tested organisms in 24-h cultures (Table 1) , with minimum bactericidal concentrations (MBCs; defined as a Ն3-log drop in CFU/ml) at 2-to 4-fold-higher compound concentrations than MICs (defined as inhibitory to growth with a Ͻ3-log drop in CFU/ml). Aerotolerant anaerobic Gram-positive bacteria (streptococci) were more resistant to killing than aerobic Gram-positive organisms (S. aureus and B. anthracis). A time course for coenzyme Q1 (50 g/ml) killing of S. aureus MN8 indicated that the compound was bactericidal by 1 h postinoculation. Coenzyme Q1 was equally antimicrobial for E. coli, Salmonella Typhimurium, and Bordetella bronchiseptica; the compound was 4-fold more active against G. vaginalis than against the other Gram negatives.
Coenzymes Q1, Q2, and Q3 inhibit exotoxin production independent of effects on bacterial growth. TSST-1 production by three S. aureus strains (MN8, CDC587, and MNPE) was inhibited by coenzyme Q1 at concentrations of Ͼ5 g/ml (MN8 strain shown in Fig. 2 ), despite not inhibiting bacterial growth at concentrations of Ͻ25 g/ml. Coenzymes Q2 and Q3 also inhibited TSST-1 production at concentrations that did not inhibit bacterial growth.
We evaluated the ability of coenzyme Q1 to inhibit production of alpha-toxin independent of S. aureus MNPE growth to determine if the toxin inhibitory effect was generalizable. As expected, coenzyme Q1 was bactericidal to strain MNPE (alpha-toxin highϩ ) at concentrations of Ն25 g/ml. However, alpha-toxin production by the strain was inhibited significantly at coenzyme Q1 concentrations of Ն3.1 g/ml (Fig. 3) .
Studies of mechanism of action. Menadione may generate toxic reactive oxygen species at concentrations of 10 g/ml or greater (27) ; this may account for its antibacterial effect. We thus tested the ability of both menadione and coenzyme Q1 to inhibit growth of S. aureus MN8 after culture anaerobically (Fig. 4) compared to growth aerobically. Menadione was bactericidal for S. aureus when grown anaerobically at Ն50 g/ml, compared to 12.5 g/ml when cultured aerobically (4-fold difference). However, complete killing of S. aureus MN8 anaerobically did not occur until 200 g/ml, compared to 12.5 g/ml aerobically (16-fold difference). Coenzyme Q1 was 2-fold more toxic to S. aureus MN8 at low coenzyme Q1 concentrations when cultured anaerobically versus aerobically (though both were bactericidal at 25 g/ml), but coenzyme Q1 did not completely kill S. aureus MN8 anaerobically until the concentration was 200 g/ml, compared to 25 g/ml when cultured aerobically (8-fold difference).
We tested the ability of coenzyme Q1 to target the SrrA/B TCS, previously shown to be an important global regulator of exotoxin production by S. aureus (28) . This was accomplished by compar- a MIC was defined as inhibiting bacterial growth but reducing CFU/ml by Ͻ3 logs in 24 h; starting inocula were 10 6 to 10 7 /ml based on the possibility of high bacterial counts on mucosal surfaces. b MBC was defined as Ն3log bacterial killing in Ͻ24 h; starting inocula were 10 6 to 10 7 /ml. c Recent clinical isolates included 2 USA200 MSSA isolates and 8 CA-MRSA isolates (2 USA200, 3 USA300, and 3 USA400). ing coenzyme Q1 activity against wild-type S. aureus MN8 and an isogenic complete srrAB knockout strain. Coenzyme Q1 was bactericidal for strain MN8 at concentrations of Ն25 g/ml, whereas the compound was bactericidal for the srrAB knockout only at 50 g/ml ( Fig. 5A ; an example is shown in Fig. 5C ) and even then was not as active as against wild type MN8. As expected (28) , the srrAB knockout strain produced more TSST-1 than wild-type strain MN8 (30 g/ml compared to 2.5 g/ml) in the absence of coenzyme Q1. However, TSST-1 production by MN8 was completely or nearly completely inhibited by coenzyme Q1 concentrations of Ն10 g/ml, whereas toxin production by the srrAB knockout strain did not occur until coenzyme Q1 concentrations of Ն25 g/ml (Fig. 5B) . Production of the cell surface protein protein A was increased at coenzyme Q1 concentrations that inhibited TSST-1 production (data not shown).
We examined the ability of coenzyme Q1 to synergize with a topical antimicrobial agent, GML, that targets bacterial plasma membranes to kill S. aureus MN8 (17, 18) . Coenzyme Q1 was bactericidal for S. aureus MN8 at 15 g/ml (Fig. 6) . In contrast, when GML (10 g/ml) was present, coenzyme Q1 was bactericidal at 2 g/ml (7.5-fold synergy). GML alone at 10 and 100 g/ml did not inhibit S. aureus MN8 growth (data not shown).
Animal studies. We examined coenzyme Q1 for ability to prevent development of staphylococcal TSS in rabbits in a subcutaneous model (Fig. 7) . In this model, 5/6 rabbits survived and did not develop symptoms of TSS when treated with coenzyme Q1. In contrast, 6/6 rabbits that received a vehicle alone succumbed to lethal TSS (P ϭ 0.015). There were no observable ill effects in healthy rabbits treated comparably with coenzyme Q1 but not microbes.
DISCUSSION
This article demonstrates the ability of menaquinone analogs to inhibit growth of Gram-positive and Gram-negative bacteria 24-h test period. S. aureus MN8 (10 7 /ml) was incubated in TH broth with various concentrations of CoQ1 or various concentrations of CoQ1 plus GML (10 g/ml). GML (100 g/ml) was not inhibitory to S. aureus.
FIG 7
Coenzyme Q1 (CoQ1) protects rabbits from TSS in a subcutaneous abscess model. Rabbits received subcutaneous Wiffle balls 6 weeks prior to experimentation for encapsulation of the Wiffle balls. The animals were then injected intra-Wiffle ball with S. aureus MN8 plus CoQ1 in ethanol or S. aureus MN8 plus ethanol. Animals were monitored for survival over a 1-week test period. P value for survival difference was determined by Fisher's exact test. (29) (30) (31) . Menadione is a precursor for menaquinone, so it was interesting that this molecule was antimicrobial for these two bacteria. Menadione at approximately 10 g/ml generates reactive oxygen species, including superoxide anions, and this may be an important mechanism of action of the compound (32, 33) . However, our studies show that menadione is also bactericidal to S. aureus grown under anaerobic conditions, though not as bactericidal as when cultured aerobically, suggesting that generation of toxic oxygen radicals is not the sole mechanism of menadione antimicrobial activity. We do not know if coenzyme Q1 molecules generate toxic reactive oxygen species when cultures are incubated aerobically, but this seems likely. However, coenzyme Q1 is more active anaerobically than aerobically when tested at low concentrations. These data suggest that menadione and possibly coenzyme Q1 exhibit bacterial toxicity in part due to superoxide anion generation, but both menadione and coenzyme Q1 are toxic to bacteria through other mechanisms. We suggest at least two possibilities. First, studies suggest that menaquinone is required as a signal molecule within bacterial plasma membranes for some TCS (12) . We recently identified the TCS SrrA/B and its homolog BrrA/B (B. anthracis respiratory response) (28, 34) . SrrA/B functions as a repressor of TSST-1 production in the absence of oxygen (28) . In the presence of Ͼ2% oxygen, SrrA/B is derepressed and TSST-1 production occurs; this has been proposed to explain the association of tampons with menstrual TSS. Through use of a complete knockout of the SrrA/B TCS compared to wild-type S. aureus, we showed that SrrA/B is at least one target of coenzyme Q1, with the compound being more effective at killing and inhibiting TSST-1 production in wild-type than SrrA/B knockout organisms. It is possible that other TCS are also affected indirectly (or directly) by coenzyme Q1. The S. aureus global regulatory system, Agr, is regulated by SrrA/B (28, 35) . Agr is a quorum sensing system that leads to exotoxin production in exponential growth phase and concurrent cessation of cell surface virulence factor production (for example, protein A) (13) . Thus, the coenzyme Q1 effect on SrrA/B could indirectly inhibit Agr upregulation of exotoxin production; protein A production could be simultaneously increased. This is similar to findings in a prior study in which we demonstrated that positively charged hemoglobin peptides target SrrA/B, and likely therefore indirectly Agr, to inhibit exotoxin production and upregulate protein A, independent of effects on growth (15) . The WalK/R system of S. aureus is required for peptidoglycan synthesis, and the TCS is required for staphylococcal survival (36) . If signaling through this system or another key TCS is altered by compounds such as coenzyme Q1, this could also explain their bacterial killing.
Second, in the yeast Saccharomyces cerevisiae, quinones been shown to form covalent bonds with and inactivate macromolecules; this may occur anaerobically as well as aerobically (27) . Thus, menadione and coenzyme Q1 may bind to and inactivate key molecules in macromolecular biosynthesis whether on the bacterial cell surface or intracellular.
It is interesting that coenzyme Q molecules are antimicrobial, dependent on length of the isoprenoid side chain. Coenzyme Q10 lacks antimicrobial activity and has 10 isoprenoid units in its side chain. In contrast, coenzyme Q1 has the greatest antimicrobial activity, having only one isoprenoid side chain. GML is another antimicrobial that broadly inhibits growth and independently inhibits exotoxins at non-growth-inhibitory concentrations (17, 18, 37) . GML has greater antibacterial activity than do monoesters with shorter fatty acid side chains. GML is proposed to interfere with TCS and dissipate the potential difference across plasma membranes (17, 18) . The similarities in overall effects of coenzyme Q1 and GML on bacteria suggest that the two compounds have related actions, but their differences as a function of side chain length suggest that their precise molecular targets are dissimilar.
We have performed multiple studies of GML topical safety and antimicrobial activity in vivo, including both nonhuman and human chronic safety studies, and human studies of effects on members of the mucosal microbial flora, including S. aureus (38) (39) (40) . We suggest that coenzymes Q1 to Q3, if subsequently shown to be safe in humans, may be useful as additives to topical microbicides containing GML to synergize with GML to increase its antimicrobial activities.
A final important finding in our studies is that coenzyme Q1 can be administered to rabbits to inhibit staphylococcal TSS production in a rabbit abscess model. In this model, rabbits administered 500 g of coenzyme Q1 alone show no signs of toxicity. Coenzyme Q1 belongs to the larger family of coenzyme Q molecules, including coenzyme Q10, which is also generally recognized as safe by the FDA for use as a health food supplement. Indeed, coenzyme Q10 is broadly used to help reduce the incidence of heart diseases, and the molecule is easily tolerated by humans at high doses (grams). It is thus possible that coenzymes Q1 to Q3 with antimicrobial activity may also be tolerated by humans.
In sum, our studies show that menadione and coenzymes Q1 to Q3 are broadly antimicrobial and independently inhibit Grampositive exotoxin production. It is possible that these molecules may become a novel class of antimicrobials that target TCS for managing bacterial infections, particularly on mucosal and skin surfaces.
